Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 312

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 312
---
 and                                     |

| ● | covenants                                                                                         
 regarding matters such as no integration with other offerings, filing of a Current Report         
 on Form 8-K to disclose the consummation of the offering and entry in securities purchase         
 agreements and the placement agency agreement, no shareholder rights plans, no material nonpublic 
 information, use of proceeds, indemnification, reservation and listing of common stock.           |

Delivery of the shares of
Common Stock, Pre-Funded Warrants and Offered Common Warrants offered hereby is expected to occur on or about February 7, 2025,
subject to satisfaction of certain customary closing conditions.

Pursuant to a side letter
between the placement agent and JonesTrading Institutional Services LLC (“Jones”), dated February 3, 2025, Jones agreed to
be a financial advisor for the offering. In connection with the services provided by Jones, the placement agent and Jones agreed that
the placement agent will receive an aggregate fee equal to up to 6% of the gross proceeds received in the offering and Jones will receive
an aggregate fee equal to up to 3% of the gross proceeds received in the offering. In addition, we have agreed to reimburse the placement
agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $85,000, non-accountable expenses of up to $25,000
and we have agreed to reimburse the financial advisor for all reasonable and documented out-of-pocket fees and expenses, including but
not limited to travel and other out-of-pocket expenses in an amount not to exceed $15,000.

We estimate the total expenses
of this offering paid or payable by us, exclusive of the placement agent’s cash fee, the financial advisor’s cash fee and
expenses of the placement agent and financial advisor, will be approximately $475,000. After deducting the fees due to the placement agent
and our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately $4.1
million.

The following table shows
the per share and total cash fees we will pay to the placement agent and financial advisor in connection with the sale of the Common
Stock, Pre-Funded Warrants, Offered Common Warrants and shares of Common Stock underlying the Pre-Funded Warrants and
Offered Common Warrants pursuant to this prospectus.

|                                  |     | Per Share          
 and Offered Common 
 Warrant            |        |     | Per Pre-Funded      
 Warrant and Offer